for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NRX Pharmaceuticals Inc

NRXP.OQ

Latest Trade

10.43USD

Change

0.00(0.00%)

Volume

997

Today's Range

--

 - 

--

52 Week Range

8.39

 - 

76.87

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.43
Open
0.00
Volume
997
3M AVG Volume
105.49
Today's High
--
Today's Low
--
52 Week High
76.87
52 Week Low
8.39
Shares Out (MIL)
53.77
Market Cap (MIL)
560.86
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2021 NRX Pharmaceuticals Inc Earnings Release

Latest Developments

More

NRX Pharmaceuticals Treatment Trial Shows Significant Relief From Respiratory Distress In Critical COVID-19

NRx Pharmaceuticals To Work With Cardinal Health To Ensure Efficient Distribution Of Potential Therapies

NRX Pharmaceuticals Initiates Phase 2B Trial Of Brilife Vaccine For COVID-19 In Nation of Georgia

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About NRX Pharmaceuticals Inc

NRX Pharmaceuticals, Inc., formerly Big Rock Partners Acquisition Corp., is a patient-focused, clinical stage pharmaceutical company. The Company is focused on developing NRX-101. NRX-101 is an oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder and ZYESAMI (aviptadil), an intravenous and inhaled drug to treat respiratory failure in COVID-19. NRX-101 is designed to offer an oral, rapid-onset and sustained home-use therapy that can extend ketamine’s anti-suicidal benefit and reduce the side effects of ketamine. The Company combines D-cycloserine (DCS), a N-methyl-D-aspartate (NMDA) receptor modulator, and lurasidone, a 5-HT2a receptor antagonist. NRX-101 is in Phase III of clinical testing.

Industry

Business Services

Contact Info

1201 N. MARKET STREET, SUITE 111

WILMINGTON, DE

19801

United States

+1.484.2546134

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
-344.11

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up